Topomer-CoMFA-based predictive modelling on 2,3-diaryl-substituted-1,3-thiazolidin-4-ones as non-nucleoside reverse transcriptase inhibitors

Medicinal Chemistry Research

Volumn 24, Issue 1, 2015, Pages 245-257

  Kumar, Surendra ^a   Tiwari, Meena ^a  

^a SHRI G S INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

3D QSAR; HIV 1; Reverse transcriptase enzyme inhibitors; Thiazolidin 4 one; Topomer CoMFA

Indexed keywords

EID: 84939893045     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-014-1105-y     Document Type: Article

References (39)

1. Balzarini J (2004) Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1. Curr Top Med Chem 4:921-944
2. Balzarini J, Orzeszko B, Maurin JK, Orzeszko A (2007) Synthesis and anti-HIV studies of 2-adamantyl-substituted thiazolidin-4-ones. Eur J Med Chem 42:993-1003
3. Balzarini J, Orzeszko-Krzesińska B, Maurin JK, Orzeszko A (2009) Synthesis and anti-HIV studies of 2-and 3-adamantyl-substituted thiazolidin-4-ones. Eur J Med Chem 44:303-311
4. Barreca ML, Carotti A, Carrieri A, Chimirri A, Monforte AM, Calace MP, Rao A (1999) Comparative molecular field analysis (CoMFA) and docking studies of non-nucleoside HIV-1 RT inhibitors (NNIs). Bioorg Med Chem 7:2283-2292
5. Barreca ML, Chimirri A, De Luca L, Monforte AM, Monforte P, Rao A, Zappala M, Balzarini J, De Clercq E, Pannecouque C, Witvrouw M (2001) Discovery of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV-1 agents. Bioorg Med Chem Lett 11:1793-1796
6. Barreca ML, Balzarini J, Chimirri A, De Clercq E, De Luca L, Höltje HD, Höltje M, Monforte AM, Monforte P, Pannecouque C, Rao A, Zappala M (2002) Design, synthesis, structure-activity relationships, and molecular modeling studies of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV agents. J Med Chem 45:5410-5413
7. Barreca ML, Chimirri A, De Clercq E, De Luca L, Monforte AM, Monforte P, Rao A, Zappala M (2003) Anti-HIV agents: design and discovery of new potent RT inhibitors. Il Farmaco 58:259-263
8. Bush BL, Nachbar RB Jr (1993) Sample-distance partial least squares: PLS optimized for many variables, with application to CoMFA. J Comput Aided Mol Des 7:587-619
9. Chimirri A, Grasso S, Molica C, Monforte AM, Monforte P, Zappala M, Bruno G, Nicolo F, Witvrouw M, Jonckeere H, Balzarini J, De Clercq E (1997) Structural features and anti-human immunodeficiency virus (HIV) activity of the isomers of 1-(2', 6'-difluorophenyl)-1H,3H-thiazolo [3,4-a] benzimidazole, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor. Antivir Chem Chemother 8:363-370
10. Chimirri A, Grasso S, Monforte AM, Monforte P, Rao A, Zappala M, Bruno G, Nicolo F, Pannecouque C, Witvrouw M, De Clercq E (1998) Synthesis, structure and in vitro anti-human immunodeficiency virus activity of novel 3-methyl-1H, 3H-thiazolo [3,4-a] benzimidazoles. Antivir Chem Chemother 9:431-438
11. Chimirri A, Grasso S, Monforte P, Rao A, Zappala M, Monforte A, Pannecouque C, Witvrouw M, Balzarini J, De Clercq E (1999) Synthesis and biological activity of novel 1H,3H-thiazolo [3,4-a] benzimidazoles: non-nucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitors. Antivir Chem Chemother 10:211-217
12. Cramer RD (2003) Topomer CoMFA: a design methodology for rapid lead optimization. J Med Chem 46:374-388
13. Cramer RD, Patterson DE, Bunce JD (1988) Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 110:5959-5967
14. Cramer RD, Cruz P, Stahl G, Curtiss WC, Campbell B, Masek BB, Soltanshahi F (2008) Virtual screening for R-groups, including predicted pIC50 contributions, within large structural databases, using topomer CoMFA. J Chem Inf Mod 48:2180-2195
15. Jilek RJ, Cramer RD (2004) Topomers: a validated protocol for their self-consistent generation. J Chem Inf Comput Sci 44:1221-1227
16. Jonckheere H, Anne J, De Clercq E (2000) The HIV-1 reverse transcription (RT) process as target for RT inhibitors. Med Res Rev 20:129-154
17. Murugesan V, Tiwari VS, Saxena R, Tripathi R, Paranjape R, Kulkarni S, Makwana N, Suryawanshi R, Katti SB (2011) Lead optimization at C-2 and N-3 positions of thiazolidin-4-ones as HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorg Med Chem 19:6919-6926
18. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338:853-860
19. Prabhakar YS, Solomon VR, Rawal RK, Gupta MK, Katti SB (2004) CP-MLR/PLS directed structure-activity modeling of the HIV-1 RT inhibitory activity of 2,3-diaryl-1,3-thiazolidin-4-ones. QSAR Comb Sci 23:234-244
20. Rao A, Carbone A, Chimirri A, De Clercq E, Monforte AM, Monforte P, Pannecouque C, Zappala M (2002) Synthesis and anti-HIV activity of 2,3-diaryl-1,3-thiazolidin-4-(thi) one derivatives. Il Farmaco 57:747-751
21. Rao A, Carbone A, Chimirri A, De Clercq E, Monforte AM, Monforte P, Pannecouque C, Zappala M (2003) Synthesis and anti-HIV activity of 2,3-diaryl-1,3-thiazolidin-4-ones. Il Farmaco 58:115-120
22. Rao A, Balzarini J, Carbone A, Chimirri A, De Clercq E, Monforte AM, Monforte P, Pannecouque C, Zappala M (2004a) 2-(2,6-Dihalophenyl)-3-(pyrimidin-2-yl)-1,3-thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors. Antivir Res 63:79-84
23. Rao A, Balzarini J, Carbone A, Chimirri A, De Clercq E, Monforte AM, Monforte P, Pannecouque C, Zappala M (2004b) Synthesis of new 2,3-diaryl-1,3-thiazolidin-4-ones as anti-HIV agents. Il Farmaco 59:33-39
24. Rawal RK, Prabhakar YS, Katti SB, De Clercq E (2005) 2-(Aryl)-3-furan-2-ylmethyl-thiazolidin-4-ones as selective HIV-RT inhibitors. Bioorg Med Chem 13:6771-6776
25. Rawal RK, Prabhakar YS, Katti SB (2007a) Molecular surface features in modeling the HIV-1 RT inhibitory activity of 2-(2, 6-disubstituted phenyl)-3-(substituted pyrimidin-2-yl)-thiazolidin-4-ones. QSAR Comb Sci 26:398-406
26. Rawal RK, Kumar A, Siddiqi MI, Katti SB (2007b) Molecular docking studies on 4-thiazolidinones as HIV-1 RT inhibitors. J Mol Mod 13:155-161
27. Rawal RK, Tripathi R, Katti SB, Pannecouque C, De Clercq E (2007c) Design, synthesis, and evaluation of 2-aryl-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents. Bioorg Med Chem 15:1725-1731
28. Rawal RK, Tripathi R, Katti SB, Pannecouque C, De Clercq E (2007d) Synthesis and evaluation of 2-(2,6-dihalophenyl)-3-pyrimidinyl-1,3-thiazolidin-4-one analogues as anti-HIV-1 agents. Bioorg Med Chem 15:3134-3142
29. Rawal RK, Tripathi RK, Katti SB, Pannecouque C, De Clercq E (2007e) Synthesis and biological evaluation of 2,3-diaryl substituted-1,3-thiazolidin-4-ones as anti-HIV agents. Med Chem 3:355-363
30. Rawal RK, Tripathi R, Katti SB, Pannecouque C, De Clercq E (2008) Design and synthesis of 2-(2,6-dibromophenyl)-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents. Eur J Med Chem 43:2800-2806
31. Ren J, Esnouf R, Garman E, Somers D, Ross C, Kirby I, Keeling J, Darby G, Jones Y, Stuart D, Stammers D (1995) High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nat Struct Biol 2:293-302
32. Schrodinger Suite 2012: Maestro, version 9.3, Schrödinger, LLC, New York, NY, 2012
33. Schrodinger Suite 2012: LigPrep, version 2.5, Schrödinger, LLC, New York, NY, 2012
34. Sweeney ZK, Klumpp K (2008) Improving non-nucleoside reverse transcriptase inhibitors for first-line treatment of HIV infection: the development pipeline and recent clinical data. Curr Opin Drug Discov Dev 11:458-470
35. SYBYL-X 2.0, Tripos International, 1699 South Hanley Rd., St. Louis, Missouri, 63144, USA
36. Tarrago-Litvak L, Andreola ML, Nevinsky GA, Sarih-Cottin L, Litvak S (1994) The reverse transcriptase of HIV-1: from enzymology to therapeutic intervention. FASEB J 8:497-503
37. Tavel JA, Miller KD, Masur H (1999) Guide to major clinical trials of antiretroviral therapy in human immunodeficiency virus-infected patients: protease inhibitors, non-nucleoside reverse transcriptase inhibitors, and nucleotide reverse transcriptase inhibitors. Clin Infect Dis 28:643-676
38. Turner BG, Summers MF (1999) Structural biology of HIV. J Mol Biol 285:1-32
39. Zhang Z, Hamatake R, Hong Z (2004) Clinical utility of current NNRTIs and perspectives of new agents in this class under development. Antivir Chem Chemother 15:121-134